About Company

• Incorporated on October 16, 1998, Indegene is a Provider of digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies and the sales and marketing of their products. Their solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. The company achieves this by combining over 2 decades of healthcare domain expertise and fit-for-purpose technology. Their portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies.

• Company’s Enterprise Commercial Solutions and Omnichannel Activation solutions cater to the commercial functions of life sciences companies while their Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions. Enterprise Commercial Solutions primarily involve assisting life sciences companies with their digital marketing operations.

• The company also provides digital asset management, marketing automation, customer data management and analytics solutions to measure the effectiveness of marketing campaigns.

• Omnichannel Activation solutions help life sciences companies leverage a “digital first” approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals HCPs across multiple channels.

• Under the Enterprise Medical Solutions, indigene establishes Centres of Excellence (“CoEs”) to consolidate large scale regulatory and medical operations for their clients.

• Indegene also offers Enterprise Clinical Solutions and consultancy services. Their Enterprise Clinical Solutions help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. They provide consultancy services through their subsidiary, DT Associates Ltd, under the “DT Consulting” brand.

• Indegene has established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the FY2023, having earned more than 69% of their total revenue from continuing operations for each of the FY2023, FY2022 and FY2021 from these 20 customers.

• Since their inception, Indegene has completed a total of 13 acquisitions, and enjoyed synergistic benefits from each of these acquisitions.

• As of December 31, 2023, Indegene had 65 active clients whom they deliver solutions from their operation hubs located across North America, Europe, and Asia.

Strengths

Business Strategies 

• Strengthen the “go to market” engine;

• Develop the technology portfolio;

• Pursue strategic acquisitions;

• Focus on operational excellence

Company Promoters

Company Financials

Indegene Limited Financial Information (Restated Consolidated)

Indegene Limited's revenue increased by 39.85% and profit after tax (PAT) rose by 63.43% between the financial year ending with March 31, 2023 and March 31, 2022.

Objects of the Issue

The Company proposes to utilise the Net Proceeds towards funding the following objects:

1. Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.;
2. Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.; and
3. General corporate purposes and inorganic growth.